Skip to main content
SpringerLink
Log in

Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma

  • Brief Report
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Coiffier B, Thieblemont C, Van Den NE et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12):2040–2045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Abramson J, Shipp M (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106(4):1164–1174

    Article  CAS  PubMed  Google Scholar 

  3. Lenz G, Staudt L (2010) Aggressive lymphomas. N Engl J Med 362(15):1417–1429

    Article  CAS  PubMed  Google Scholar 

  4. Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. 4th edition. IARC Press, Lyon, France, pp. 233–237

    Google Scholar 

  5. Rimsza LM, Roberts RA, Miller TP et al (2004) Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the leukemia and lymphoma molecular profiling project. Blood 103(11):4251–4258

    Article  CAS  PubMed  Google Scholar 

  6. Roberts RA, Wright G, Rosenwald AR et al (2006) Loss of MHC class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108(1):311–318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rimsza L, Leblanc ML, Unger JM et al (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112(8):3425–3433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Puvvada SD, Li H, Rimsza LM et al (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57(10):2359–2369

    Article  CAS  PubMed  Google Scholar 

  9. Schmelz M, Montes-Moreno S, Piris MA, Wilkinson ST, Rimsza LM (2012) Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica 97(10):1614–1161

    Article  PubMed  PubMed Central  Google Scholar 

  10. List AF, Spier CM, Miller TP, Grogan TM (1993) Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 7(3):398–403

    CAS  PubMed  Google Scholar 

  11. Chang KC, Huang GC, Jones D, Lin YH (2007) Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 13(22):6666–6672

    Article  CAS  PubMed  Google Scholar 

  12. Rimsza LM, Roberts RA, Campo E et al (2006) Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 107(3):1101–1107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rimsza LM, Chan WC, Gascoyne RD et al (2009) CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 94(4):596–598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wilkinson ST, Fernandez DR, Murphy SP et al (2009) Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Leuk Lymphoma 50(11):1875–1878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wilkinson ST, Vanpatten KA, Fernandez DR et al (2012) Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 119(6):1459–1467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Redd L, Schmelz M, Burack R, Cook JR, Day AW, Rimsza L (2016) Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. J Hematopathology DOI. doi:10.1007/s12308-016-0272-9

    Google Scholar 

  17. Meyer PN, Fu K, Greiner TC et al (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207

  18. Johnson N, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Diepstra A, van Imhoff G, Karim-Kos H et al (2007) HLA class II expression by Hodgkin reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 25(21):3101–3108

    Article  PubMed  Google Scholar 

  20. Ahmadzadeh M, Johnson LA, Heemskerk B et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537–1544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fourcade J, Kudela P, Sun Z et al (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182(9):5240–5249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported by The Hope Foundation/SWOG Development Award (Grant Agreement 2012) and by a Lymphoma Research Foundation Post-Doctoral Fellowship (2558183). We thank the University of Arizona Statistics Consulting Laboratory and Center for Biomedical Informatics and Biostatistics for performing the multivariate survival analysis.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA

    Samantha Kendrick & Monika Schmelz

  2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA

    Lisa M Rimsza

  3. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada

    David W Scott, Joseph M. Connors, Laurie Sehn & Randy D Gascoyne

  4. Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada

    Graham W Slack, Pedro Farinha, King L Tan & Randy D Gascoyne

  5. University of Arizona Cancer Center, Tucson, AZ, USA

    Daniel Persky & Soham Puvvada

Authors
  1. Samantha Kendrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa M Rimsza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Graham W Slack
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pedro Farinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. King L Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel Persky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soham Puvvada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joseph M. Connors
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Laurie Sehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Randy D Gascoyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Monika Schmelz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Schmelz.

Ethics declarations

Conflicts of interests

The authors declare that they have no conflict of interest.

Informed consent

The Institutional Review Board of the University of British Columbia/BC Cancer Agency in accordance with the Declaration of Helsinki approved the use of these human tissues and clinical data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kendrick, S., Rimsza, L.M., Scott, D.W. et al. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch 470, 113–117 (2017). https://doi.org/10.1007/s00428-016-2041-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-016-2041-7

Keywords

Search

Navigation